Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Yu. M. Gomon"'
Publikováno v:
Фармакоэкономика, Vol 16, Iss 3, Pp 412-421 (2023)
Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).Materials and methods. The calculat
Externí odkaz:
https://doaj.org/article/a69dbc3671b74c419ba6104b11825fae
Autor:
Yu. M. Gomon
Publikováno v:
Реальная клиническая практика: данные и доказательства, Vol 3, Iss 3, Pp 1-7 (2023)
A review of the literature concerning the efficacy and safety of combined anti-pseudomonas protected ureidopenicillin piperacillin/tazobactam usage. Randomized clinical trials and their meta-analysis have demonstrated that piperacillin/ tazobactam am
Externí odkaz:
https://doaj.org/article/1437a47fd3b94a138796d2c4c098b9b6
Publikováno v:
Реальная клиническая практика: данные и доказательства, Vol 3, Iss 2, Pp 21-30 (2023)
Pharmacoepidemiological studies are necessary to improve the system of rational use of drugs and to identify the most problematic areas. Such studies make it possible to evaluate not only quantitative indicators of consumption but also indicators suc
Externí odkaz:
https://doaj.org/article/13b248ad76fd41ba9efd1f3d182172d2
Autor:
Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina
Publikováno v:
Антибиотики и Химиотерапия, Vol 68, Iss 3-4, Pp 52-65 (2023)
Aim. Evaluation of the effectiveness of anti-interleukin drugs used in the pathogenetic therapy of COVID-19 in relation to the relative risks of 28-day mortality and the odds ratio of 14-day improvement of symptoms of the disease. Materials and metho
Externí odkaz:
https://doaj.org/article/618a2d426e9b4b53bfefda881fa2d316
Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 34-46 (2023)
Aims. To consider factors associated with adverse outcome among hospitalized patients with moderate and severe COVID-19.Materials and methods. Data from 345 case histories of adult patients hospitalized with moderate to severe COVID-19 were analyzed
Externí odkaz:
https://doaj.org/article/0c15f6e78e42461db8a237c9b55caf49
Autor:
Yu. M. Gomon, A. R. Kasimova, A. S. Kolbin, V. V. Strizheletsky, I. G. Ivanov, S. O. Mazurenko
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 3, Pp 283-292 (2022)
Most of the medicines used to treat the novel coronavirus infection (COVID-19) are either approved under an accelerated procedure or not approved for the indication. Consequently, their safety requires special attention.The aim of the study was to re
Externí odkaz:
https://doaj.org/article/415405402b884605b93bdb4dcf047e8c
Autor:
Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A. S. Kolbin, M. V. Livshits, T. A. Usmanova, A. M. Fakhrutdinova, Yu. S. Konstantinova, A. P. Gubanov
Publikováno v:
Фармакоэкономика, Vol 16, Iss 1 (2023)
Objective: evaluation of the clinical and economic efficiency of using Levilimab in the treatment of moderate and severe COVID-19 based on real world data (RWD).Material and methods. A single-center observational retrospective case-control study was
Externí odkaz:
https://doaj.org/article/f1aa28e0503a48149650f97a89964f5e
Publikováno v:
Фармакоэкономика, Vol 15, Iss 1, Pp 87-105 (2022)
Objective: to assess the compliance of the actual practice of conducting clinical and economic research with the requirements applicable in the Russian Federation (RF) when including drugs in the Federal Program of High-Cost Nosologies (HCN).Material
Externí odkaz:
https://doaj.org/article/411137fa18374be49b88cd7009aea2a7
Publikováno v:
Фармакоэкономика, Vol 15, Iss 1, Pp 145-161 (2022)
Introduction. As defined by the Food and Drug Administration, real-world data (RWD) is data related to a patient's health and/or health care delivery, usually collected from various sources as part of real-world clinical practice research.Objective:
Externí odkaz:
https://doaj.org/article/64e816634c6e4a088fd0b9c4112da2e2
Autor:
A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 24-34 (2021)
Relevance. Assessment of the burden of disease provides information on the economic consequences of the disease, allows you to assess the social significance, identify areas that require additional clinical and economic research, changes in methodolo
Externí odkaz:
https://doaj.org/article/13d7f3968de044ce9588129c5030d73a